Summit Therapeutics and AstraZeneca Announce $2 Billion Equity Investment Agreement
Summit Therapeutics (SMMT) has entered into an agreement with AstraZeneca (AZN), under which the latter will invest $2 billion in convertible preferred shares. The deal was announced on Monday, leading to a more than 17% increase for Summit's stock during extended trading. The investment is expected to provide significant financial support and strategic alignment between the two companies. AstraZeneca’s involvement signals confidence in Summit Therapeutics' pipeline or business strategy.
Topics: convertible preferred shares equity investment stock price movement